Alzheimer’s disease
Alzheimer’s disease is the most common form of dementia. For decades, researchers have sought a treatment to no avail, and our understanding of the condition is now being questioned. This Outlook lays bare the problems, the disagreements and the reasons to be hopeful.
This Nature Outlook is editorially independent. It is produced with third party financial support. About this content.
-
Produced with support from:
-
Produced with support from:
-
Funded by a grant from:
This Nature Outlook is editorially independent, produced with financial support from a third party. About this content.
Nature is pleased to acknowledge the financial support of Biogen Inc. and Eisai Co., Ltd. in producing this Outlook. Additional funding was provided by a grant from Merck & Co., Inc., Kenilworth, New Jersey. The sponsors retain sole responsibility for the following messages.
About the Joint Development Agreement between Biogen and Eisai for Alzheimer’s Disease
Biogen and Eisai are widely collaborating on the joint development and commercialization of investigational drugs for Alzheimer’s disease.
About Biogen
At Biogen, our mission is clear: we are pioneers in neuroscience. Biogen discovers, develops and delivers worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases.
To learn more, please visit www.biogen.com and follow us on social media – Twitter, LinkedIn, Facebook, Youtube.
About Eisai Co., Ltd.
Eisai Co., Ltd. is a leading global research and development-based pharmaceutical company headquartered in Japan. We define our corporate mission as “giving first thought to patients and their families and to increasing the benefits health care provides,” which we call our human health care (hhc) philosophy. As a pioneer in the field of dementia treatment, Eisai is striving to not only develop next generation treatments but also to develop diagnosis methods and provide solutions.
For more information about Eisai Co., Ltd., please visit www.eisai.com
Produced with support of a grant from Merck & Co., Inc., Kenilworth, New Jersey
